Navigation Links
US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
Date:2/28/2008

es and Risks

During the fourth quarter of 2005, we received a subpoena from the United States Department of Justice's Civil Litigation Division ("DOJ") requesting a broad range of information about us and our business, generally in relation to our contracts and relationships with pharmaceutical manufacturers. We are cooperating fully with the DOJ in responding to the subpoena. At the present time, the DOJ has not made any allegation of wrongdoing on the part of the Company. We cannot, however, provide assurance that such an allegation or litigation will not result from this investigation.

On April 18, 2006, the Company terminated its net revenue model comprehensive service agreement with a practice in Oklahoma, as a result of alleged breaches of that agreement by the practice. The practice accounted for 4.6 percent and 2.3 percent of the Company's revenue and EBITDA, respectively, for the first quarter of 2006. The Company remains in litigation with this practice regarding termination of its service agreement. As a result of the practice's alleged breaches of that agreement and the litigation, we were unable to collect payments on receivables owned by us and other amounts owed by the practice on a timely basis. At December 31, 2007, the total amount owed to us for those receivables of $22.5 million is reflected on our balance sheet as other assets. We intend to pursue the claims we incurred as a result of terminating this service agreement. We also intend to defend against the practice's allegations that we breached the agreement and that the agreement is unenforceable. As with any complex litigation, the process necessary to resolve this claim may take several years.

During March 2007, the Company became aware that it and one of its affiliated practices are the subject of allegations that the practice may have engaged in activities that violate the Federal False Claims Act. These allegations are contained in a qui tam complaint, commonly referr
'/>"/>

SOURCE US Oncology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related biology technology :

1. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
2. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
3. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
4. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
5. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
6. PRA International to Present Audioconference on Oncology Research - Nov. 8
7. IMPAC Medical Systems to Offer Revenue Cycle Inc.s Array of Oncology Products and Services to Customers
8. AG Mednet to Provide Image Network for Southwest Oncology Group
9. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
10. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
11. Oncology Metrics and Cureline Announce Joint Marketing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 On January, 14, 2015, ... Washington D.C. science community to the UMBC campus for ... by the Protein Society, will take place from 9 ... 312. Through discussion, presentations and workshops, the free ... proteins, their role in the industry and the future ...
(Date:11/26/2014)... Sunnyvale, CA (PRWEB) November 25, 2014 ... joins forces with RPM Alliance , provider ... and pharmaceutical companies. With the latest addition to its ... only free validated EDC system to India. , ... as a robust and customizable EDC platform which is ...
(Date:11/26/2014)... November 26, 2014 SoundConnect , ... is proud to announce that Darren Suders has joined ... Darren will drive the partner program ... experience. , Darren brings more than 10-years ... key roles in channel operations, from policy development, to ...
(Date:11/26/2014)... 25 novembre 2014 /PRNewswrie/ -- Theravalues Corporation annuncia con ... europeo in occasione di Hi Europe 2014 (dal 2 ... Si tratta della curcumina con la maggiore biodisponibilità ... cristalli) e ingredienti approvati dalle norme europee. ... della pianta curcumina ( Curcuma longa ) che è ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3
... , , WATERTOWN, Mass., Sept. 10 ... breakthrough synthetic chemistry technology announced today that it will ... on the synthesis and antibacterial activity of analogs from ... at the 49th Interscience Conference on Antimicrobial Agents and ...
... STOCKHOLM, September 10 Pergamum AB has announced ... wound healing interests, and create a broad-based therapeutic ... The Pergamum product pipeline consists of five ... Indications covered within the,portfolio include improved wound healing ...
... , , , ... Inc. (PTC) today announced the initiation of a Phase 3 ... in patients with nonsense mutation cystic fibrosis (nmCF). Patients ... conductance regulator (CFTR) protein, a chloride channel necessary for normal ...
Cached Biology Technology:Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009 2Pergamum to Provide Effective Development of Innovative Dermatology and Wound Healing Companies 2PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 2PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 3PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 4PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 5PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 6
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
(Date:11/7/2014)... professor, biomedical engineering, in the Grove School of ... have identified a molecule that could lead to ... forms of breast cancer. , Triple negative breast ... to aggressive proliferation and metastasis and a lack ... discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) ...
(Date:11/6/2014)... predator. Except when that predator runs so fast that it ... size, is the fastest creature on Earth. Some of these ... about five miles per hour). The fastest human can do ... the tiger beetle, a person would have to hit 480 ... problem. At peak speeds, everything becomes a blur. They can,t ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3The tiger beetle: Too fast to see 2
... novel method of collecting and storing carbon dioxide that will ... The quest to capture carbon dioxide is crucial to ... compressed and safely stored. It is also a ... and require several stages of refining and extraction before a ...
... antibiotic and anti-cancer chemicals may one day be synthesised ... that combine to provide soldier beetles with their potent ... Sweden,s Karolinska Institute, published details of the gene identification ... Nature Communications ., "For the first time, our ...
... skin and well-armored bodies. So it comes as something of a ... the most acute in the animal kingdom. The crocodilian sense ... that dot their skin all over their body. In alligators, the ... study, published in the Nov. 8 issue of the Journal ...
Cached Biology News:Capturing carbon with clever trapdoors 2Gene find turns soldier beetle defence into biotech opportunity 2Despite their thick skins, alligators and crocodiles are surprisingly touchy 2Despite their thick skins, alligators and crocodiles are surprisingly touchy 3
... system for fluorescent light due to small ... camera to detect low level light in ... disease research, gene expression, circadian rhythm, gels ... imager with a motor-driven camera inside the ...
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
...
Biology Products: